. . " "@en . . "Ena 713 Free Base"@en . . . . "40%"@en . . . . . . . . . . . . . . . . . . . . . . "* renal cl=2.1-2.8 L/hr"@en . . . . . "Venkata Naga Brahmeswara Rao Mandava, Venkata Reddy Vajrala, Ganesh Varanasi, Vijay Kumar Adla, Mukund Reddy Jambula, Vijaypal Reddy Kanumathi Reddy, \"PREPARATION OF RIVASTIGMINE AND ITS SALTS.\" U.S. Patent US20080255383, issued October 16, 2008."@en . . . . "Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces."@en . . . . . . . "Rivastigmine"@en . . . . . . . . . . . . "Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase."@en . . . "* 1.8 to 2.7 L/kg"@en . . "m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate"@en . "approved"@en . "investigational"@en . "# Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12369954 # Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10066203 # Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15336465 # Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11568422 # Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15590953 # Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19370562# Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19470293 # Farlow MR: Update on rivastigmine. Neurologist. 2003 Sep;9(5):230-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14587496"@en . "Humans and other mammals"@en . . . "Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues."@en . . . "For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type."@en . . "1.5 hours"@en . . . . . . . . . . . . . . . . . . "(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate"@en . "123441-03-2"@en . . . . . .